On heels of psych drug approval, BioXcel dives head first into oncology R&D with new cash infusion

Two weeks after New Haven, CT biotech BioXcel Therapeutics won FDA approval for the psychiatric drug Igalmi, the biotech is making a major new move: pivoting its focus to commercialization and spinning out much of the rest of its pipeline into a new company.